- Santen Pharmaceutical Co., Ltd. press release ( OTCPK:SNPHY ): Q3 GAAP EPS of ¥54.11.
- Revenue of ¥199.8B (+2.0% Y/Y).
For further details see:
Santen Pharmaceutical Co., Ltd. GAAP EPS of ¥54.11, revenue of ¥199.8Bhome / stock / snphy / snphy news
For further details see:
Santen Pharmaceutical Co., Ltd. GAAP EPS of ¥54.11, revenue of ¥199.8BMarket Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
Santen Pharmaceutical Co. Ltd. ADR Company Name:
SNPHY Stock Symbol:
Market:
OSAKA, Japan and SAN DIEGO, March 09, 2020 (GLOBE NEWSWIRE) -- Santen Pharmaceutical Co., Ltd. (Head Office: Osaka; hereinafter, “Santen”) and TRACON Pharmaceuticals, Inc. (Head Office: San Diego, CA; hereinafter, “TRACON”) today announced the discontinuation of ...